AirSculpt Technologies (AIRS) 27th Annual ICR Conference 2025 summary

Business overview and market opportunity

• Operates 32 centers offering minimally invasive body contouring, with a patented procedure and strong brand recognition.

• Targets a large total addressable market (TAM) estimated at $11 billion, with current revenue under $200 million.

• Procedures include fat removal, fat transfer, and skin tightening, with permanent results and rapid recovery.

• Business model is cash-based, with no insurance or accounts receivable, and leverages elite cosmetic surgeons.

• GLP-1 weight loss drugs are seen as complementary, creating further demand for skin tightening and fat transfer.

Financial performance and growth

• 2023 revenue reached $196 million, up 16% year-over-year, with $43 million EBITDA and 22% EBITDA margin.

• Average procedure generates $12,000–$13,000 in revenue and $8,000 in gross profit.

• De novo centers cost $1.5 million to open, become cash flow positive in 3–4 months, and achieve 100% return on capital in year one.

• Since 2019, revenue grew from $41 million to $196 million, a 37% CAGR, with EBITDA rising from $7 million to $43 million.

• Free cash flow funds new center openings, with over 130 potential U.S. markets identified for expansion.

Recent challenges and strategic focus

• 2024 saw revenue decline to $180 million and adjusted EBITDA to $20.5 million, attributed to macroeconomic headwinds in the aesthetics sector.

• Conversion rates have softened, but lead interest remains high.

• New CEO is prioritizing a transformation focused on culture and revenue growth, with a direct-to-consumer approach.

• Five key areas under review: marketing efficiency, sales process, technology, product innovation, and de novo strategy.

• Emphasis on team alignment and proactive change management to drive turnaround and capture market opportunity.